A chemotherapy-free-based regimen of the TKI ponatinib combined with targeted immunotherapy showed significant benefits in ...

Neoadjuvant TKI therapy in non-metastatic GIST patients can reduce surgical complexity, with CE-CT imaging predicting benefits in 22 of 39 patients. Significant tumor volume reduction was observed ...

Investigators sought compare the efficacy and safety of a chemo-free approach to TKI + chemotherapy in newly-diagnosed adult Ph+ ALL.

In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.

Tyrosine kinase inhibitors (TKI) are employed to attack specific types of cancer cells. The downside to using TKs is that they can cause serious inflammation. A team of researchers has discovered the ...

The TKI plus InO-based therapy for newly diagnosed Ph+ ALL successfully met the efficacy end point, achieving an 81% MR3+ rate within 2 courses with limited cycles of InO. The modified schema 2 ...

Adding tucatinib to first-line maintenance therapy with trastuzumab/pertuzumab extends PFS for patients with previously-treated HER2+ metastatic breast cancer.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...